Avoid low quality assets in a sector where price discovery has been relentless over many years. Stay with tier 1 players. Margin of safety is in business first and not the entry price. This is not valid for short term positional trades. Those are managed via strict stop losses.
Speciality vs Commodity Chemicals
— Sajal Kapoor (@unseenvalue) June 15, 2020
Speciality - typically bespoke solutions as per customer's requirements. High complexity. This makes continous R&D and product innovation a key success factor!
Go to 2 hr 21 mins for my views on #Chemicals sector \U0001f447https://t.co/Zzx6AwHZLH
More from Sajal Kapoor
@oldschoolinvest I said 20-25% #CDMO (Synthesis) growth going forward in @IIC_Conference June 2020 conclave. They have delivered better than my expectations.
Never Knowingly Misguide.
Money making and fake advisory/PMS propaganda has never been my agenda
Never Knowingly Misguide.
Money making and fake advisory/PMS propaganda has never been my agenda
In just 15 years, #LaurusLabs has scaled up like no other..!
— Conviction | Patience (@unseenvalue) July 5, 2020
Numbers v Narrative: Well balanced 2800 Cr sales + huge competitive advantage in terms of IP/patents/synthesis capability!
Comparing Laurus with others - 1 hrs 28 mins\U0001f447https://t.co/Zzx6AwHZLH
Conviction | Patience pic.twitter.com/I6bImfjDCW
More from Uvlearnings
You offer me 80% cost arbitrage (discount relative to Japan/EU/US) along with low confidence / assurance on Critical Success Factors and I won't give you a single NCE/NBE to discover, develop or manufacture. Capex/opex arbitrage is too low in the disruptive-science-pecking-order! https://t.co/O2l8dK4BUv
![](https://pbs.twimg.com/media/E8hqg1wXMAES66g.jpg)
@unseenvalue Given high capex/opex cost structures of US/Japan/EU, how will they be able to compete with Indian API companies? https://t.co/OYhC2PUZpL
— Hiren (@hiren_investing) August 11, 2021